After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

Researchers at the Department of Mechanical Engineering, Seoul National University, have applied the principle of interlacing ...

Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech ...

As AI dominates headlines, who’s really building it? We explore how a rules-based framework distinguishes companies ...

Retail sentiment toward Recursion Pharmaceuticals (RXRX) leaned bearish ahead of its first-quarter earnings on Monday, as traders expressed caution despite encouraging preliminary data from the ...

The key is to balance offense and defense. by Leandro DalleMule and Thomas H. Davenport More than ever, the ability to manage torrents of data is critical to a company’s success. But even with the ...

Probabilistic models, such as hidden Markov models or Bayesian networks, are commonly used to model biological data. Much of their popularity can be attributed to the existence of efficient and robust ...